Literature DB >> 26492092

Histology of Pericardial Tissue Substitutes Used in Congenital Heart Surgery.

Amara Majeed1, Christopher Baird2, Michele J Borisuk2, Stephen P Sanders1, Robert F Padera3.   

Abstract

Pericardium is used as a tissue substitute during pediatric heart surgery. However, little is known about the histological characteristics of pericardial tissue substitutes. We searched our clinical and Pathology databases to identify cases in which glutaraldehyde-preserved autologous pericardium, PhotoFix bovine pericardium, or Peri-Guard Repair Patch glutaraldehyde-preserved bovine pericardium was used as patch material during cardiac surgery and in which explanted tissue substitute was available for histologic examination. Tissue sections were stained with hematoxylin and eosin, Masson trichrome, and Movat pentachrome, and were graded for inflammation, tissue substitute degeneration, neointima formation, and calcification. Nonparametric statistical methods were used to test differences between groups because of small sample size. The eight patients who received PhotoFix pericardium were older (median 10 months vs 10 days, P < 0.05) and the material was in situ longer (median 14 vs 2.5 months, P < 0.05) compared to the eight who received autologous pericardium. Only three patients received glutaraldehyde-preserved bovine pericardium precluding statistical comparison. Inflammation and tissue degeneration were greater in PhotoFix pericardium compared to autologous pericardium but were no more than moderate. Neointima formation and calcification did not differ significantly between the two groups. PhotoFix bovine pericardium is associated with more inflammation and material degeneration but calcification, and neointima formation are similar to autologous pericardium. Although the short-term outcomes are acceptable, calcification and degeneration seen in some cases suggest that long-term outcomes and performance at certain anatomic locations need further study.

Entities:  

Keywords:  CHD; Pediatric; Pericardium

Mesh:

Year:  2015        PMID: 26492092     DOI: 10.2350/15-08-1696-OA.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  5 in total

1.  The fate of the fresh autologous pericardium after right ventricular outflow tract reconstruction.

Authors:  Hassan Tatari; Gholamreza Omrani; Maedeh Arabian; Kambiz Mozaffari; Yaser Toloueitabar; Sanaz Asadian; Nader Givtaj; Maziar Gholampour Dehaki; Amirhosein Jalali
Journal:  J Cardiovasc Thorac Res       Date:  2022-03-07

2.  Congenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model.

Authors:  Vladica M Veličković; Oleg Borisenko; Mikael Svensson; Tim Spelman; Uwe Siebert
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

3.  A Comprehensive Comparison of Bovine and Porcine Decellularized Pericardia: New Insights for Surgical Applications.

Authors:  Sabra Zouhair; Eleonora Dal Sasso; Sugat R Tuladhar; Catia Fidalgo; Luca Vedovelli; Andrea Filippi; Giulia Borile; Andrea Bagno; Massimo Marchesan; De Rossi Giorgio; Dario Gregori; Willem F Wolkers; Filippo Romanato; Sotirios Korossis; Gino Gerosa; Laura Iop
Journal:  Biomolecules       Date:  2020-02-28

Review 4.  Promoting Cardiac Regeneration and Repair Using Acellular Biomaterials.

Authors:  Vishnu Vasanthan; Ali Fatehi Hassanabad; Simranjit Pattar; Paul Niklewski; Karl Wagner; Paul W M Fedak
Journal:  Front Bioeng Biotechnol       Date:  2020-04-17

5.  Vascular Remodeling of Clinically Used Patches and Decellularized Pericardial Matrices Recellularized with Autologous or Allogeneic Cells in a Porcine Carotid Artery Model.

Authors:  Jaroslav Chlupac; Roman Matejka; Miroslav Konarik; Robert Novotny; Zuzana Simunkova; Iveta Mrazova; Ondrej Fabian; Milan Zapletal; Zdenek Pulda; Jan Falk Lipensky; Jana Stepanovska; Karel Hanzalek; Antonin Broz; Tomas Novak; Alena Lodererova; Ludek Voska; Theodor Adla; Jiri Fronek; Miroslav Rozkot; Serhiy Forostyak; Peter Kneppo; Lucie Bacakova; Jan Pirk
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.